Individual patents are often particularly valuable in the pharmaceuticals sector. After all, the patents relate to a precious commodity: our health. Behind each property right there are often huge investments as well as numerous jobs and research and sales organizations. This means that pharmaceutical companies should think carefully about who they entrust their patent to. Us, for example. At COHAUSZ & FLORACK, pharmaceuticals are always a partnership thing!
How do you protect your product from generics?
Pharmaceutical research companies that invest a great deal of R&D in their products face major challenges today. We, the COHAUSZ & FLORACK partners, represent your interests effectively, especially to competitors and generic manufacturers. Highly complex patent infringement proceedings are a standard part of our legal services. We are happy to support your company in any challenge the market throws at you!
In order to defend your intellectual property rights, especially against generic manufacturers, it is necessary to successfully defend oppositions to the grant of patents before the European Patent Office (EPO) and nullity actions before the German Federal Patent Court (BPatG) or the Unified Patent Court (UPC). Opposition proceedings are usually very complex and run in different countries simultaneously. This requires a great deal of coordination and interdisciplinary collaboration. You can count on us: with unique expertise, excellent contacts, exceptional dedication and commitment to detail and an uncompromising will to win and a talent for developing winning strategies, we represent your interests effectively - especially against competitors and generics manufacturers.
We have everything you need from a strong partner to support you in the IP sector:
- exceptional expertise
- many years of experience
- strong identification with you and your product
- reliability
- trust
... and much more! We look forward to empowering your company and ensuring that it remains innovative in the long term!
Long-standing Cohausz & Florack partners retire
Andreas Thielmann, Dr. Thomas Rox, and Hans-Joachim Meyer leave the firm after many successful years as patent attorneys
Strong global growth in electricity grid technologies
C&F: “Important sign that we are on the way to an energy transition”